Blockade of cannabinoid type 1 (CB 1)-receptor signaling decreases the rewarding
properties of many drugs of abuse and has been proposed as an anti-addiction strategy …

Opioid analgesics represent a critical treatment for chronic pain in the analgesic ladder of
the World Health Organization. However, their use can result in a number of unwanted side …

Background Activation of cannabinoid CB 1 receptors suppresses pathological pain but also
produces unwanted central side effects. We hypothesized that a positive allosteric modulator …

Background Cannabinoid CB 1 receptors play an essential role in drug addiction. Given the
side effect profiles of orthosteric CB 1 antagonism, new strategies have been attempted to …

Recently, multiple compounds have been synthesized that target the allosteric binding site
(s) of CB 1. These CB 1 positive allosteric modulators may capture the benefits of …

Opioid use disorder reflects a major public health crisis of morbidity and mortality in which
opioid withdrawal often contributes to continued use. However, current medications that treat …

Drug addiction is a chronic relapsing disorder that produces a dramatic global health burden
worldwide. Not effective treatment of drug addiction is currently available probably due to the …

The opioid crisis has underscored the urgent need to identify safe and effective therapeutic
strategies to overcome opioid-induced liabilities. We recently reported that LY2828360, a …

AM1710 (3-(1, 1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo (c) chromen-6-one), a
cannabilactone cannabinoid receptor 2 (CB2) agonist, suppresses chemotherapy-induced …

This review examines the development of cannabinoid CB1 receptor antagonists as a new
class of therapeutic agents for drug addiction. Abused drugs [alcohol, opiates, Δ9 …